Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Whole Foods merger complaint

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission issues an amended complaint Sept. 8 against Whole Foods' acquisition of Wild Oats Markets, claiming the already-completed merger is "substantially reducing or eliminating competition in the operation of premium natural and organic supermarkets" in several geographic markets. The respondent has until Sept. 26 to file a response. FTC's complaint follows a same-day scheduling conference in which an administrative law judge from the agency laid out a timeline for filings and discovery leading up to a hearing before the commission on Feb. 16, 2009. The amended complaint filing was enabled by a July decision by the U.S. Court of Appeals for the District of Columbia Circuit, which reversed a lower court's ruling against FTC's motion for a preliminary injunction against the merger (1"The Tan Sheet" Aug. 18, 2008, p. 6). Whole Foods filed a petition Aug. 26 for a rehearing before the appeals court

You may also be interested in...

Whole Foods Merger Ruling Could “Embolden” Antitrust Activity – Attorney

An appeals court's questions about a merger in a key market for dietary supplement manufacturers - the Whole Foods/Wild Oats Markets deal - may impede similar deals across all U.S. industries, an antitrust law expert says

Not Too Late? German Industry Presses For EU MRA With Post-Brexit UK

BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December. 

ESMO: Daiichi's HER3-Targeting ADC Shows Promise, Particularly In Resistant Tumors

HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts